| 0.4663 0.003 (0.61%) | 04-19 09:41 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.74  |
1-year : | 0.89 |
| Resists | First : | 0.63 |
Second : | 0.76 |
| Pivot price | 0.6 |
|||
| Supports | First : | 0.41 | Second : | 0.34 |
| MAs | MA(5) : | 0.5 |
MA(20) : | 0.62 |
| MA(100) : | 0.85 |
MA(250) : | 1.06 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 12  |
D(3) : | 11.2 |
| RSI | RSI(14): 17 |
|||
| 52-week | High : | 1.67 | Low : | 0.41 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ HUGE ] has closed above bottom band by 5.6%. Bollinger Bands are 39.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.5 - 0.5 | 0.5 - 0.5 |
| Low: | 0.43 - 0.44 | 0.44 - 0.44 |
| Close: | 0.46 - 0.47 | 0.47 - 0.47 |
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.
Wed, 17 Apr 2024
FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and ... - Chronicle-Tribune
Wed, 17 Apr 2024
FSD Pharma Inc. | Nation and World | corsicanadailysun.com - Corsicana Daily Sun
Wed, 17 Apr 2024
FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and ... - Yahoo Finance
Mon, 15 Apr 2024
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can ... - Victoria Advocate
Tue, 09 Apr 2024
FSD Pharma Faces Nasdaq Compliance Challenge - TipRanks.com - TipRanks
Tue, 02 Apr 2024
FSD Pharma cuts losses and expenses for 2023 - Green Market Report
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 40 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 17.3 (%) |
| Held by Institutions | 2.5 (%) |
| Shares Short | 333 (K) |
| Shares Short P.Month | 364 (K) |
| EPS | -0.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.34 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -43.1 % |
| Return on Equity (ttm) | -84 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -1.02 |
| PEG Ratio | 0 |
| Price to Book value | 1.36 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|